Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | SQLE | Q14534 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
| ▸ | FNTB | P49356 | 2/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16892784 | 1.00 | KMT2A (0.57) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL15516075 | 1.00 | KMT2A (0.57) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL31406757 | 0.90 | KMT2A (0.70) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL31406758 | 0.90 | KMT2A (0.70) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL31406762 | 0.90 | KMT2A (0.70) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL2495182 | 0.88 | KMT2A (0.65) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL12635063 | 0.80 | FNTA (0.56) | KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL11152268 | 0.80 | — | — | |
| SCHEMBL10445540 | 0.79 | KMT2A (0.58) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10445541 | 0.79 | KMT2A (0.58) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9284246-B2 | Method for producing optically active 2,3-dihydrofarnesal | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-03-15 | — | — | US | disclosed |
| US-20150218072-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| EP-2894143-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | Takasago International Corporation (JP) | 2015-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218072-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | FNTB, FNTA, LSS | KMT2A 4528/4885ALOX15 181/4885MAPT 3669/4885 |
| US-20160152550-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2,3-DIHYDROFARNESAL | FNTB, FNTA, LSS | KMT2A 4528/4885ALOX15 181/4885MAPT 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.